High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas

Abstract Background Immunotherapy has demonstrated encouraging clinical benefits in patients with advanced breast carcinomas and Programmed death ligand 1 (PD-L1) expression has been proposed as an immunotherapy biomarker. Challenges with current PD-L1 testing exist and tumor mutation burden (TMB) i...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Ping Mei (Awdur), C. Eric Freitag (Awdur), Lai Wei (Awdur), Yunxiang Zhang (Awdur), Anil V. Parwani (Awdur), Zaibo Li (Awdur)
Fformat: Llyfr
Cyhoeddwyd: BMC, 2020-05-01T00:00:00Z.
Pynciau:
Mynediad Ar-lein:Connect to this object online.
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Rhyngrwyd

Connect to this object online.

3rd Floor Main Library

Manylion daliadau o 3rd Floor Main Library
Rhif Galw: A1234.567
Copi 1 Ar gael